Merck and Daiichi Sankyo have voluntarily withdrawn their Biologics License Application for ifinatamab deruxtecan (I-DXd) for extensive-stage small cell lung cancer in the U.S. This decision follows discussions with the FDA, which indicated that the submitted data, including from the IDeate-Lung01 trial, did not meet the requirements for accelerated approval. This withdrawal represents a setback for the companies' oncology pipeline in this specific indication.
Merck and Daiichi Sankyo have withdrawn their Biologics License Application for ifinatamab deruxtecan (I-DXd) for extensive-stage small cell lung cancer in the U.S. The withdrawal stems from FDA discussions indicating that the data, particularly from the IDeate-Lung01 Phase 2 trial, was insufficient for accelerated approval. This is a negative development for both companies, as it delays or potentially halts the market entry of a promising drug candidate for an unmet medical need. In the short term, this could lead to a negative sentiment for MRK and Daiichi Sankyo, impacting their stock prices. Long-term, it raises questions about the future development path for I-DXd in this indication and the companies' ability to meet regulatory standards. Traders should consider the potential for downward pressure on these stocks due to this regulatory setback.